Detalhe da pesquisa
1.
Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer.
J Immunother Cancer
; 11(10)2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37852738